Stockreport

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 [Yahoo! Finance]

Valneva SE - American Depositary Shares  (VALN) 
PDF LimmaTech Biologics AG , a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant [Read more]